February 10, 2026

@michaelokun

Can a skin pump smooth dopamine delivery in Parkinson’s disease? A fresh look at subcutaneous levodopa. Subcutaneous means medication is delivered under the skin using a small pump to provide more continuous drug levels, rather than pills taken by mouth. Burton and colleagues describe in a new paper in European Journal of Neurology how subcutaneous levodopa infusions compared w/ oral levodopa for reducing motor fluctuations in Parkinson’s disease and they based their conclusions on a systematic review and meta-analysis. Key Points: - Subcutaneous levodopa significantly reduced daily OFF time compared w/ oral levodopa when examined across multiple clinical trials. - Improvements were also seen in quality of life and sleep scores, though the magnitude varied between studies. - Infusion site reactions were common, and overall adverse events were more frequent than w/ oral therapy. My take: This review reinforces that subcutaneous dopamine is an important option for many folks w/ Parkinson’s disease. Continuous delivery can meaningfully reduce OFF time for many folks, however convenience, tolerability and long-term adherence will usually shape who benefits most. Here are 5 points that resonated w/ me: 1- Reducing OFF time by nearly two hours a day is clinically meaningful for many folks. 2- Continuous subcutaneous delivery aims to smooth dopamine levels, rather than push higher peaks. 3- Benefits appear consistent across different subcutaneous formulations. 4- Infusion site issues are real and require proactive education and support from health care providers. 5- This approach expands the menu of advanced therapies between pills, intestinal gels and surgery for Parkinson’s disease. https://onlinelibrary.wiley.com/doi/10.1111/ene.70506 #michaelokun #fixelinstitute #parkinson